

**Amendments to the Claims**

1-20. (Cancelled)

21. (Currently amended) A method of increasing cerebral bioavailability of a **simvastatin** ~~[physiologically active]~~ composition in an individual comprising introducing the composition into the blood stream of the individual substantially contemporaneously with a blood flow enhancing amount of L-arginine.

22. (Currently amended) A method of increasing cerebral bioavailability of a **simvastatin** ~~[physiologically active]~~ composition in an individual ~~[according to claim 20]~~ comprising introducing the composition into the blood stream of the individual substantially contemporaneously with a blood flow enhancing amount of an agent which increases the production of NO by preexisting ecNOS and at least one other NO-increasing agent, **wherein the agent which increases the production of NO by preexisting ecNOS is selected from the group consisting of L-arginine, NADPH, and tetrahydrobiopterin.**

23. (Cancelled).

24. (Previously presented) The method according to claim **22** ~~[[23]]~~, further wherein the agent which increases the production of NO by preexisting ecNOS is L-arginine.

25. (Previously presented) The method according to claim 22, wherein the agent which increases the production of NO by preexisting ecNOS is L-arginine and the at least one other NO-increasing agent is a different an agent which increases the production of NO by preexisting ecNOS.

26. (Previously presented) The method according to claim 22, wherein the agent which increases the production of NO by preexisting ecNOS is L-arginine and the at least one other NO-increasing agent is a non-ecNOS NO-generating system.

27. (Currently amended) The method according to any one of claims **21, 22 and 24-26**~~[20 to 22]~~ wherein the individual ~~[in need of enhanced drug delivery]~~ has experienced, is experiencing, or has an abnormally elevated risk of experiencing an ischemic stroke.

28. (Currently amended) The method according to any one of claims 21, 22 and 24-26 [~~20 to 22~~] wherein the simvastatin [~~physiologically active~~] composition has a site of action in the brain.

29-35. (Cancelled)